Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ikaria, NuPathe File Initial Public Offerings

This article was originally published in The Pink Sheet Daily

Executive Summary

Weak performance by a smattering of biotechs that went public in early 2010 hasn't deterred two more from being first to register this year.

You may also be interested in...

Ikaria’s Hybrid Business Model Taps Big Pharma Trends

Although Ikaria focuses on a highly specialized segment of the hospital market, its integrated business model offers insights into continuum of care strategies that pharma companies are evaluating in a reimbursement-focused world. The company’s promising strategy could get a boost from key trial read-outs as soon as late 2012.

Alimera Raises $72 Million In IPO; Clips Share Price To $11 From Initial $15-$17 Range

$15 million will be used to pay debt to Australian drug maker pSivida, which gave Alimera its lead compound.

Ikaria Backers Buy INO, Create Model for Self-Funding Discovery

Ikaria's private-equity funded acquisition of INO Therapeutics will allow the company to self-fund its continuing discovery programs while acting as a magnet for additional external commercial or clinical stage projects.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts